Andria Chastain, President and Clay Dehn, Chief Scientific OfficerEstablished in 2013 by Lori Wright, who remains Chief Executive Officer, ERG began as a multidisciplinary research network committed to scientific excellence and operational precision. Since its founding, the company has driven research forward in psychiatry, neurology, analgesia, early-phase clinical pharmacology, metabolism, and endocrinology. Guided by Lori Wright’s vision, ERG was built to translate scientific insight into high-quality clinical execution while anticipating the evolving needs of the industry.
Under Lori Wright’s leadership, ERG has steadily expanded both its scientific depth and operational reach. The strategic addition of endocrinologist Dr. Sherwyn Schwartz, in 2018, followed by Chief Scientific Officer Clay Dehn, PhD(c), significantly bolstered the company’s foundation in metabolic and obesity research. As global attention shifted toward obesity, ERG was uniquely positioned- with the expertise, infrastructure, and foresight- to lead in this rapidly evolving therapeutic area.
Andria Chastain, President of ERG, characterizes the company’s evolution as both proactive and strategic.
GLP-1 therapies are already being studied for their potential benefits in addiction, Alzheimer’s and dementia. Given our experience in psychiatry and neurology, we are well-positioned to support sponsors as these compounds move into those therapeutic areas.
Responding to Industry Shifts with Scientific Rigor
Under the scientific leadership of Clay Dehn, ERG plays an active role in shaping the national landscape metabolic and obesity research. As ERG’s representative to the Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium, Dehn serves on the Metabolic Disorders Steering Committee. Through these strategic collaborations, ERG continues to advance solutions to critical challenges in metabolic disorder drug development, with a particular focus on obesity.
With over two decades of leadership in endocrine and metabolic research, Clay Dehn, describes the field as one of constant evolution:
“Diabetes once defined the scope of metabolic research, followed by the emergence of fatty liver disease. We recognized early that obesity would become the dominant focus and proactively pivoted to ensure our capabilities aligned with our clients’ evolving needs.”
Building Scientific Strength Through Technology, Training and Expertise
To ensure industry-leading support across all service lines, ERG established an internal Obesity Task Force composed of experts from medical and scientific affairs, operations, recruitment, and other core disciplines. Operating at both the strategic program and service-offering levels, the task force drives company-wide initiatives that enhance the design and integration of obesity and metabolic studies. By promoting consistency, efficiency, and scientific rigor across the network, the group strengthens ERG’s ability to anticipate sponsor needs and deliver cohesive, high-quality clinical support.
Among the task force’s key initiatives is Everybody Research, ERG’s proprietary digital participant-recruitment platform. Since its launch, the platform has expanded the company’s database of overweight and obese participant from 80,000 in 2024 to more than 200,000 in 2025- growing by approximately 10,000 new profiles each month. By directly connecting volunteers to relevant clinical studies, Everybody Research accelerates recruitment timelines, enhances demographic diversity, and improves the generalizability of study populations across ERG’s twenty wholly-owned clinical sites nationwide.
In parallel, ERG is advancing investigator development through its Obesity Medicine Certification initiative. Currently, seven physician-investigators across the network are either certified by the American Board of Obesity Medicine (ABOM) or actively pursuing certification. The program’s goal is to ensure at least one ABOM-certified investigator at each site, establishing a foundation of specialized expertise that supports the increasing complexity of obesity drug development.
ERG’s commitment to scientific discipline is exemplified by its Unified Site Methodology program, which standardizes training and clinical conduct across all locations. From anthropometric procedure- such as waist and hip circumference measurements performed to WHO or NHANES specifications- to complex pharmacodynamic assessments like indirect calorimetry and glucose clamps, protocols are harmonized to ensure data integrity and reproducibility.
“Our Unified Site Methodology ensures consistency and rigor across every study we conduct,” says Andria Chastain, highlighting how ERG differentiates itself from other research networks.
-
We recognized early that metabolic research would shape modern healthcare. Our goal has always been to build a scientific foundation that adapts with industry needs.
“Our Unified Site Methodology ensures consistency and rigor across every study we conduct,” says Andria Chastain, highlighting how ERG differentiates itself from other research networks.
Addressing Industry Challenges through Innovation and Collaboration
As global obesity research continues to advance, one persistent challenge remains: maintaining data completeness and interpretability in long-duration trials. Missing data- often resulting from participant discontinuation or withdrawal can compromise the precision of treatment-effect estimates and delay the development of new therapeutic strategies. While this affects nearly every disease area, it is particularly pronounced in obesity trials where patients often have high elevated expectations for weight loss outcomes especially in light of the transformative impact of GLP-1 therapies.
To address the persistent challenge of missing data in long duration obesity trials, ERG is spearheading an interdisciplinary initiative to pioneer the use of digital twin technology in obesity drug development. This approach leverages individualized, model-based trajectories of weight and related outcomes to serve as robust comparators when observed data are incomplete. By enhancing analytical precision and reducing bias, digital twins offer a scientifically grounded, regulatory-aligned solution to mitigate the impact of missing data. This initiative reflects ERG’s commitment to innovation and its collaboration with leading technology partners to strengthen data integrity and improve the reliability of trial outcomes.
Alongside digital innovation, ERG continues to refine its Unified Site Methodology through internal research. The company is validating an enhancement to improve repeatability of standardized anthropometric measures, including waist and hip circumference. This reflects ERG’s commitment to advancing clinical precision and harmonized methodology across its network.
Together, these efforts embody ERG’s philosophy that research should not only advance science but also improve how science is conducted. Through collaboration, innovation, and methodological rigor, ERG continues to shape the future of obesity and metabolic research drug development.
Expanding Horizons beyond Metabolism
As ERG’s leadership in metabolic and obesity research grows, its multidisciplinary expertise positions the organization to explore adjacent therapeutic frontiers. Incretin-based therapies, now central to obesity treatment, are increasingly being studied for potential benefits in neurological and psychiatric disorders-areas where ERG also has deep clinical experience. This convergence of metabolic and neurobehavioral capabilities offers a distinct advantage, enabling ERG to support sponsors pursuing cross-disciplinary development programs.
“GLP-1 therapies are already explored for potential benefits in addiction, Alzheimer’s and dementia,” notes Clay Dehn. “With our experience in psychiatry and neurology, ERG is well-positioned to support sponsors as these compounds expand into new therapeutic areas.”
ERG’s organizational structure supports its evolving focus, operating across five therapeutic pillars: psychiatry, neurology, metabolism and endocrinology, early-phase clinical pharmacology, and analgesia. Each area is led by dedicated medical and operational experts, enabling ERG to identify cross-therapeutic insights- particularly at the intersection of metabolic and neurological sciences.
Beyond execution, ERG actively contributes to scientific advancement through global forums. The company has presented findings on the neurocognitive effects of incretin therapies at the American Diabetes Association and Obesity Week. These engagements help shape dialogue on emerging trends in metabolic and neurobehavioral research, fostering collaboration among academia, industry, and regulators to advance therapeutic innovation.
Shaping the Future of Clinical Research
ERG’s next phase of growth is centers on scalability and scientific depth. With a robust research pipeline projected over the next three years, the company aims to expand its obesity and metabolic capabilities while upholding the rigorous standards that define its success.
The Scientific Leadership Team (SLT)- comprising industry experts, key opinion leaders, and principal investigators- plays a central role in this effort. Meeting twice weekly, the SLT evaluates new projects from both scientific and operational perspectives, ensuring every study aligns with ERG’s core principles: data integrity, participant safety, and measurable scientific value.
ERG’s evolution demonstrates how an organization can anticipate industry shifts and build enduring leadership through foresight, collaboration, and scientific focus. By integrating medical expertise with technology and patient-centered design, ERG is advancing metabolic and obesity research while shaping the future of clinical innovation.
Choosing an Anti-Obesity Clinical Trial Partner in a Far More Demanding Market
Anti-obesity drug development has become one of the most competitive and closely watched areas in biotechnology. A few years ago, sponsors were largely focused on proving weight reduction. Today, the expectations are far more complicated. Clinical programs now have to account for treatment adherence, dropout rates, placebo frustration, side effects, lean-mass concerns and the reality that obesity treatment often becomes long-term care rather than a short intervention. For sponsors, the challenge is no longer just scientific validation. It is generating reliable data while keeping patients engaged long enough for the evidence to remain meaningful.
That shift has changed what companies look for in a clinical trial partner. Recruitment scale still matters, but access alone is no longer enough. Obesity and type 2 diabetes trials are competing for many of the same patient populations, and some markets have already seen participant fatigue from repeated enrollment outreach. Research organizations with outdated databases or overly broad advertising strategies often struggle to maintain enrollment quality over time. Stronger operators usually rely on continuously refreshed participant pools, structured prescreening processes and a better understanding of how to recruit across varying obesity classes and comorbidity profiles.
Retention has become equally important. Anti-obesity trials can face dropout pressure for reasons that have little to do with study quality itself. Participants may experience side effects, lose motivation after landing in placebo groups or compare the trial experience to commercial treatment options outside the study. Sponsors increasingly value research teams that think carefully about participant communication, lifestyle counseling consistency and expectation management from the beginning of the protocol process. Keeping patients engaged is often what protects endpoint integrity later.
Measurement consistency has also become a bigger issue than many sponsors initially expect. Obesity trials depend heavily on data points like weight, waist circumference, hip circumference, neck circumference and dietary tracking. Those measurements sound straightforward, but even small differences in collection methods between technicians or sites can distort outcomes, particularly in smaller cohorts or early-stage studies. Research organizations with strong operational discipline tend to standardize training aggressively, align sites around validated procedures and minimize collection variability wherever possible. That consistency gives sponsors greater confidence that observed changes reflect actual biological response rather than uneven site execution.
Scientific breadth is becoming another differentiator as obesity research expands into adjacent therapeutic categories. Incretin-based therapies are already being explored in addiction, neurodegenerative disease and broader metabolic conditions alongside obesity itself. Sponsors working in this space increasingly benefit from partners that understand how metabolism overlaps with psychiatry, neurology, fatty liver disease and diabetes rather than organizations focused narrowly on high-volume recruitment alone. Investigators with cross-disciplinary experience can often identify feasibility concerns and protocol weaknesses much earlier in development.
Evolution Research Group has built much of its anti-obesity clinical trial infrastructure around those operational realities. Its recruitment ecosystem includes the Join a Research Study platform, MyTrialApp and the Every Body Research initiative, all designed to support participant outreach and engagement. The organization has also developed a large obesity-focused participant database alongside specialized efforts around investigator certification, lifestyle-counseling alignment and standardized site methodology. Combined with experience spanning metabolism, psychiatry, neurology, clinical pharmacology and analgesia, the company is positioned for sponsors that need recruitment, retention and measurement discipline working together rather than operating in silos.
...Read more
Anti-Obesity Drug Development Clinical Trial Services Info
Q1
What has positioned Evolution Research Group among Top Anti-Obesity Drug Development Clinical Trial Services providers?
Scientific specialization and extensive metabolic research capabilities have helped Evolution Research Group establish a strong reputation among Top Anti-Obesity Drug Development Clinical Trial Services providers. The company supports obesity-focused clinical development through integrated research infrastructure, experienced investigators and specialized therapeutic expertise. Its work emphasizes efficient study execution, patient recruitment and data quality across obesity and metabolic disease trials. This focused research model has strengthened Evolution Research Group’s standing within anti-obesity drug development clinical trial services.
Q2
How does Evolution Research Group differentiate its obesity clinical research approach?
Evolution Research Group applies a targeted clinical research strategy built around therapeutic specialization and operational consistency. Instead of managing obesity studies through generalized clinical frameworks alone, the company structures its anti-obesity drug development clinical trial services around dedicated obesity expertise, unified study methodologies and specialized site capabilities. Its clinical teams support both early-phase and later-stage research programs designed to evaluate metabolic therapies with greater precision. This focused therapeutic approach gives the company a differentiated position within anti-obesity drug development clinical trial services.
Q3
How does the company support obesity-focused clinical development programs?
Reliable obesity clinical trials require efficient recruitment, standardized assessments and consistent study execution. Evolution Research Group supports anti-obesity drug development clinical trial services through integrated site networks, investigator expertise and centralized operational processes designed to improve research quality. Its obesity-focused infrastructure includes specialized clinical units and methodologies that support accurate endpoint measurement and improved study consistency. By aligning operational execution with metabolic research requirements, the company contributes to more dependable clinical development outcomes.
Q4
What role does scientific expertise play in Evolution Research Group’s services?
Clinical and metabolic research expertise remain central to the company’s development strategy. Evolution Research Group applies therapeutic knowledge, clinical oversight and obesity-focused scientific capabilities to strengthen anti-obesity drug development clinical trial services across multiple research phases. Its teams support studies involving emerging obesity therapies, biomarkers and metabolic treatment approaches. This emphasis on specialized therapeutic understanding enables the company to address the growing complexity of obesity-focused drug development programs.
Q5
How do anti-obesity drug development clinical trial services create value through Evolution Research Group?
Clinical development value depends on accurate data generation, efficient patient enrollment and reliable study management. Evolution Research Group delivers anti-obesity drug development clinical trial services that help sponsors improve study efficiency, strengthen endpoint consistency and support informed development decisions. Its integrated research infrastructure also contributes to reduced operational variability and improved trial execution across obesity-focused studies. This balance between scientific rigor and operational coordination increases the practical value of the company’s clinical research capabilities.
Q6
Why is Evolution Research Group relevant to the future of obesity drug development?
Interest in obesity therapeutics continues to expand alongside advances in metabolic science and next-generation weight management therapies. Evolution Research Group contributes to this evolving landscape through anti-obesity drug development clinical trial services focused on specialized obesity expertise, clinical precision and scalable research operations. Its emphasis on standardized methodologies and therapeutic specialization aligns with industry priorities surrounding obesity research quality and regulatory confidence. As obesity drug pipelines continue to grow, the company remains relevant to the future of metabolic clinical development.
